… Multi-institutional randomized phase II trial of gefitinib for previously treated patients with
advanced non-small-… Results of a randomized phase III study to compare the overall survival of …

… 鄄small鄄cell lung cancer(INTEREST):a randomised phase Ⅲ trial[J].Lancet,2008,372(…
Phase III study,V鄄15鄄 32,of gefitinib versus docetaxel in previously treated Japanese patients …

… survival benefit of Gefitinib [32]. This failure led to intense comparative studies of lung cancer
… Subsequently, multiple prospective randomized clinical trials have established that first line …

… in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced
lung … A randomized, double-blind phase III study of icotinib versus gefitinib in patients with …

… (CP)in never or light former smokers with advanced lung adenoear- … Phase II trial of
cetuximab and erlotinib in patients with lung edenocarcinoma and acquired re· …

… Randomized phase III trial of docetaxel versus vinorelbine or ifostamide in patients with
advanced nosmall-cell lung cancer previously … of tumors to gefitinib and erlotinib.Proc Natl Acad …

… has a good efficacy and tolerability in Chinese patients with advanced non-small cell lung
cancer (NSCLC) compared with gefitinib. This retrospective study aims to evaluate the ef?cacy …

… Conclusions Compared with chemotherapy, NSCLC patients receiving EGFR‑TKI, especially
gefitinib, have higher … Randomized phase II trial of erlotinib or standard chemotherapy in …

… Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who
are never or light former … -cell lung cancer after failure of erlotinib, gefitinib, or both, and one …

… phase Ⅲ trials comparing EGFR-TKI with chemotherapy as the first-line treatment for NSCLC
patients … results from a randomized phase Ⅲ trial comparing gefitinib with carboplatin-…